Clearmind Advances CMND-100 to Patient Testing in Alcohol Use Disorder Trial

Key Points

• Clearmind Medicine Inc. received unanimous approval from an independent Data and Safety Monitoring Board to advance its CMND-100 Phase I/II trial.
• The decision followed Part A, in which the company said CMND-100 met its primary safety endpoint in healthy participants.
• The next phase will test CMND-100 in people with moderate to severe alcohol use disorder, creating the first opportunity to evaluate early patient-based clinical activity.
• The development milestone is positive, but CMND-100 remains an early-stage drug candidate with no efficacy data yet reported in AUD patients.

Clearmind Medicine (Nasdaq: CMND) announced that its independent DSMB reviewed the Part A safety dataset for CMND-100 and unanimously approved moving the clinical program into Parts B and C.

Part A enrolled healthy participants and evaluated increasing dose levels. The company reported a favorable safety and tolerability profile across the planned doses, allowing the program to proceed under its existing study protocol. These results are a necessary step in drug development, but they do not demonstrate that CMND-100 can reduce drinking or alcohol cravings.

Part B Will Test CMND-100 in AUD Patients

Part B will evaluate CMND-100 in patients with moderate to severe alcohol use disorder for the first time. Clearmind plans to enroll two sequential cohorts of six patients each, with one cohort receiving an 80 mg dose and the other receiving a 160 mg dose.

The study will assess safety and tolerability while looking for initial signs of clinical activity, including possible reductions in alcohol consumption and cravings. For investors, these first patient results are likely to be a more meaningful catalyst than the earlier healthy-volunteer safety findings.

Part C Adds Repeated-Dose Safety Data

Clearmind will conduct Part C at the same time as Part B. This portion will enroll healthy participants and evaluate a 160 mg daily dose of CMND-100 over five consecutive days in a double-blind, placebo-controlled setting.

The goal is to collect additional data on repeated-dose safety and tolerability. The overall Phase I/II program is designed to assess safety, drug exposure, and preliminary efficacy measures related to drinking patterns and alcohol cravings.

CMND-100 Is Still an Early Clinical Asset

CMND-100 is Clearmind’s proprietary oral MEAI-based drug candidate. The company is developing it as a non-hallucinogenic, second-generation neuroplastogen-derived treatment for alcohol use disorder.

The multicenter study is being conducted at Johns Hopkins University, Yale School of Medicine, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center. The trial is registered as NCT05913752.

Investors Await Patient Data and Program Updates

The DSMB approval allows Clearmind to move beyond healthy-subject testing, but the company has not provided a timeline for completing Parts B and C or releasing data. The patient cohorts are also small, so any early findings would need to be validated in larger studies.

Investors may monitor:

• Enrollment and completion of the two AUD patient cohorts
• Safety and tolerability at the 80 mg and 160 mg dose levels
• Reported changes in alcohol consumption and craving measures
• Pharmacokinetic findings and repeated-dose safety data
• Clearmind’s cash position and funding requirements for further clinical development

CMND-100 has not been approved for any use. Its ability to advance will depend on continued safety findings, evidence of patient benefit, regulatory engagement, and Clearmind’s ability to finance additional trials.